14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PFE vs MRNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PFE carries a Unified Composite Score of 49.4/100 (HOLD) at $27.40 (9.3x Forward P/E, 29.1% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).
Growth vs. Quality Trade-Off: PFE earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.18β · 22% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($980M)
90D Engineering Disclosures0 Published · mRNA Therapeutics
Investor FAQ PFE vs MRNA Key Questions & Quantitative Answers
As of Nov 20, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PFE carries a Unified Composite Score of 49.4/100 (HOLD) at $27.40 (9.3x Forward P/E, 29.1% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: PFE earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.18β · 22% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
PFE leads the Growth & Scale pillar: PFE posts -0.4% YoY revenue growth and -9.7% YoY earnings growth on $63.6B TTM revenue (74.9% gross margin, 29.1% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PFE cumulative revenue shifted +53.3% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, PFE deploys 45.8% of Rev ($29.1B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.
PFE screens cheaper on headline valuation multiples. PFE trades at 9.3x Forward P/E, 39.3x Trailing P/E, 8.56x PEG, and 3.4x EV/Revenue (18.5% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PFE (4.5% ROE) versus MRNA (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, PFE carries 48.1% implied volatility (58th %ile, Balanced (25th–60th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.18β · 22% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.